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Inﬂammatory signaling pathways orchestrate the cellular response to infection and injury. These pathways
are known to be modulated by compounds that alkylate cysteinyl thiols. One class of phytochemicals
with strong thiol alkylating activity is the chalcones. In this study we tested fourteen chalcone derivatives,
α-X-substituted 2’,3,4,4’-tetramethoxychalcones (α-X-TMCs, X = H, F, Cl, Br, I, CN, Me, p-NO2-C6H4, Ph,
p-OMe-C6H4, NO2, CF3, COOEt, COOH), for their ability to modulate inﬂammatory responses, as moni-
tored by their inﬂuence on heme oxygenase-1 (HO-1) activity, inducible nitric oxide synthase (iNOS)
activity, and cytokine expression levels. We conﬁrmed that the transcriptional activity of Nrf2 was activated
by α-X-TMCs while for NF-κB it was inhibited. For most α-X-TMCs, anti-inﬂammatory activity was posi-
tively correlated with thiol alkylating activity, i.e. stronger electrophiles (X = CF3, Br and Cl) being more
potent. Notably, this correlation did not hold true for the strongest electrophiles (X = CN and NO2) which
were found to be ineﬀective as anti-inﬂammatory compounds. These results emphasize the idea that
chemical ﬁne-tuning of electrophilicity is needed to achieve and optimize desired therapeutic eﬀects.
Introduction
The expression of anti-inflammatory proteins, such as heme
oxygenase-1 (HO-1), and proinflammatory proteins, such as
inducible NO synthase (iNOS), can be modulated by protein
thiol modifications. In particular, the oxidation of protein
thiols or their alkylation by electrophiles, especially α,β-un-
saturated carbonyl compounds (often referred to as Michael
acceptors since they are able to undergo 1,4-additions with
thiols, see Fig. 2A)1 leads to either activation or inhibition of
individual transcription factors. Alkylation of Keap12 releases
the transcription factor Nrf2 and thus induces HO-1
expression (Fig. 2B). The inactivation of NF-κB3 by Michael
acceptors4 inhibits expression of proinflammatory proteins
(e.g. iNOS, TNF, IL-6, IL-8) and appears to be mediated by
either inhibition of IκBα kinase (IKK) (Fig. 2C, Inhibition I)5 or
by alkylation of NF-κB cysteinyl residues within the DNA-
binding domain6 (Fig. 2C, Inhibition II). For example, the
natural chalcone xanthohumol was found to covalently modify
cysteinyl residues of both NF-κB p65 and IKK.5 However, the
activation of Nrf2 and inactivation of NF-κB by protein thiol
modifications may also be caused more indirectly through glu-
tathione (GSH) depletion or oxidation.7
The anti-inflammatory activity of chalcones is of significant
biomedical interest. Precise tuning of chalcone thiol reactivity
may lead to derivatives with improved therapeutic potential.
To modulate the chemical reactivity in thia-Michael additions
a substituent can be introduced in the α-position of the α,β-un-
saturated carbonyl system (Fig. 2A). Compounds with diﬀerent
substituents in the α-position can then be screened for desired
biological activities.8 We previously established a panel of four-
teen α-X-substituted 2′,3,4,4′-tetramethoxychalcones (α-X-TMCs,
Fig. 1) exhibiting a wide range of chemical reactivity. We
observed that increased chalcone thiol reactivity correlated with
stronger induction of HO-1 and stronger repression of iNOS.8b
Using a selection of cell-based assays, we now further demon-
strate that α-X-TMCs diﬀerentially aﬀect the Nrf2 and NF-κB
inflammatory response pathways within living cells.
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production and Table S1: C10 values of Nrf2 induction. See DOI: 10.1039/
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Results and discussion
α-X-TMCs induce HO-1 activity in RAW264.7 macrophages
Using our recently developed ELISA-based HO-1 assay,9
α-X-TMCs were tested for their ability to induce HO-1 activity
in RAW264.7 macrophages (Fig. 3). All α-X-TMCs were used at
a concentration of 1 µM, except for α-CF3-TMC, which is cyto-
toxic at this concentration8b and therefore was used at 0.5 µM.
HO-1 activity was determined after 3, 6 and 24 h of treat-
ment with α-X-TMCs. Most of the α-X-TMCs stimulated HO-1
activity weakly, with a maximal increase of 2.7 fold after 6 h of
treatment in the case of α-CF3-TMC. The derivatives α-CF3-
TMC, α-Br-TMC, α-H-TMC and α-Cl-TMC exhibited the most
significant eﬀect (2.1–2.7 fold of control). Induced HO-1
activity peaked at 6 h, with the exception of α-I-TMC which
induced even higher activity at 24 h (1.9 fold induction).
Overall, these findings agree well with our previous study,
which showed that α-X-TMCs with intermediate to high elec-
trophilicity (i.e. α-CF3-TMC, α-Br-TMC, α-Cl-TMC and
α-H-TMC) eﬃciently induce HO-1 protein expression at the
same concentrations (0.5, 1 µM).8b Likewise, as seen previous-
ly,8b the strongest electrophiles, α-CN-TMC and α-NO2-TMC
did not cause significant induction of HO-1 activity at 1 µM
within the same time frame. This may be due to a direct reac-
tion with GSH,10 potentially competing with the modification
of protein thiols.
α-X-TMCs induce Nrf2 activity in AREc32 cells
Having observed induction of HO-1 activity by α-X-TMCs
(Fig. 3), we then asked whether this eﬀect was caused by the
activation of Nrf2, a key transcription factor for HO-1
Fig. 1 Structures of α-X-2’,3,4,4’-tetramethoxychalcones (α-X-TMCs)
tested in this study together with the natural products xanthohumol
(XN) and curcumin which served as positive controls. Second-order rate
constants (k2) for the reaction with cysteamine are given in
parentheses.8
Fig. 2 Inﬂuence of α,β-unsaturated carbonyl compounds, acting as Michael acceptors, on transcription factors involved in inﬂammation. (A)
Michael addition leading to protein-electrophile adducts; possible inﬂuence of Michael acceptors (α,β) on the Keap1-Nrf2 pathway (B) and on the
NF-κB pathway (C). α,β, α,β-unsaturated carbonyl compound; Keap1, Kelch-like ECH-associated protein 1; Nrf2, nuclear factor-erythroid 2-related
factor 2; ARE/EpRE, antioxidant response element/electrophile response element; HO-1, heme oxygenase-1; IκBα, inhibitory factor κBα; NF-κB,
nuclear factor κ-light-chain-enhancer of activated B cells; IKK, inhibitor of nuclear factor κ-B kinase; IL-6, IL-8, interleukin-6, interleukin-8; iNOS,
inducible NO synthase; TNF, tumor necrosis factor.
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expression. Nrf2 activation was quantified in human breast
cancer MCF7 cells expressing a luciferase reporter construct
under the control of the human ARE (antioxidant response
element) core sequence (AREc32 cells).11 The α-X-TMCs were
applied for 24 h at concentrations ranging from 1.56 to
100 µM. In parallel, cytotoxicity was assessed by sulforhoda-
mine B (SRB) staining.12 Only compound concentrations
causing less than 50% cytotoxicity were included in the data
analysis. Values were normalized to the established Nrf2-
inducer xanthohumol (XN) which in our assay activated
Nrf2 maximally at 25 µM with 42 ± 11 fold induction (taken for
normalization as 100%) relative to the solvent control (Fig. 4).
The best Nrf2 activators were α-CF3-TMC (219% of XN at
3.13 µM), α-Br-TMC (317% of XN at 6.25 µM) and α-Cl-TMC
(180% of XN at 6.25 µM), which mirrors their eﬀectiveness in
inducing HO-1 expression and activity. Similar values of
maximal Nrf2 induction showed α-H-TMC (147% of XN) and
α-I-TMC (206% of XN), however at a higher concentration (25
µM). Weak electrophiles (α-COOH-TMC, α-p-OMe-C6H4-TMC,
α-F-TMC, and α-Ph-TMC) were less eﬀective than XN (16–44%),
even at higher concentrations (25, 50 or 100 µM). Overall, and
similar to HO-1 activity, k2 values (Fig. 1)
8 correlated with the
ability of α-X-TMCs to induce Nrf2 activity (Fig. 4). In agree-
ment with our previous results on HO-1 expression,8b the
α-X-aromatic compound α-p-NO2-C6H4-TMC activated Nrf2
only at very high concentrations (161% of XN at 100 µM).
While α-NO2-TMC was slightly active (31% of XN at 50 µM),
α-CN-TMC was completely inactive, again suggesting that the
two strongest electrophiles in our panel are ineﬀective in indu-
cing Nrf2 dependent gene expression.
Some of the compounds enhanced Nrf2 activity by 10 fold
at a very low concentration, as quantified by their C10 values
(Table S1†). α-CF3-TMC (C10 = 0.495 µM) was most potent, fol-
lowed by α-Br-TMC (1.39 µM), α-Cl-TMC (2.46 µM), α-I-TMC
(5.94 µM), α-H-TMC (7.23 µM) and XN (10.4 µM). C10 values
strongly correlated with maximal Nrf2 activation (Fig. 4) and
with thiol reactivity k2 values (Fig. 1).
The unexpectedly high C10 values of α-p-NO2-C6H4-TMC
(14.8 µM) and α-COOEt-TMC (18.3 µM) may indicate
additional intracellular interactions caused by the substituent
X, potentially interfering with the electrophilic reactions that
lead to Nrf2 activation.
α-X-TMCs inhibit iNOS-dependent NO production in
LPS-stimulated RAW264.7 macrophages
Next we asked to what extent the diﬀerent α-X-TMCs inhibit
NF-κB-dependent gene expression. To this end we quantified
iNOS-dependent NO production by LPS-stimulated
RAW264.7 macrophages using the Griess assay13 (Table 1). In
our previous study we already observed a significant corre-
lation between k2 values and the ability of α-X-TMCs to inhibit
iNOS activity.8b This correlation was established for the series
X = CF3, Br, Cl, I, H, and F, which are the α-X-TMCs with inter-
mediate to strong, but not very strong electrophilicity, and
for which X is not expected to engage in extra H bonding or
π-interactions.
Fig. 3 Inﬂuence of α-X-TMCs on HO-1 activity. RAW264.7 cells were treated with diﬀerent α-X-TMCs at 1 µM (0.5 µM for α-CF3-TMC) for the indi-
cated times (3, 6 and 24 h). Labels indicate the substituent X in the α-position of the α,β-unsaturated carbonyl moiety of the chalcone (p-NO2 is
short for p-NO2-C4H6 and p-OMe for p-OMe-C4H6). HO-1 activity was determined by an ELISA-based bilirubin quantiﬁcation assay. At least three
independent measurements were performed. Levels of signiﬁcance: ***, p < 0.001; **, p < 0.01; *, p < 0.05.
Fig. 4 Maximum Nrf2 induction of α-X-TMCs relative to the maximum
Nrf2 induction of the positive control xanthohumol (XN*) (set to 100%).
Activities were tested by incubating α-X-TMCs at diﬀerent concen-
trations (1.56–100 µM) for 24 h with AREc32 cells. α-CN-TMC showed
no eﬀect and thus was not included. Data points represent the mean of
2–3 independent measurements.
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Using diﬀerent non-toxic concentrations we determined the
IC50 values for the inhibition of NO production (Table 1). With
the exception of α-Me-TMC and α-p-OMe-C6H4-TMC, all
α-X-TMCs inhibited NO generation. α-p-OMe-C6H4-TMC was com-
pletely inactive, while α-Me-TMC even enhanced NO production
by 35%. Most compounds revealed a concentration-dependent
inhibitory eﬀect on NO production, with the exception of
α-CN-TMC (see ESI Fig. S1†). While the strongest inhibition of
NO release was achieved by treatment with 10 µM α-H-TMC (97%
inhibition, Table 1), the most potent chalcone was α-CF3-TMC
causing 85% inhibition at a concentration of 0.5 µM.
For seven α-X-TMCs it was possible to calculate IC50 values
for the inhibition of NO production. These correlated very well
with the corresponding k2 values, in the following order: α-CF3-
TMC (IC50 = 120 nM) < α-Br-TMC (640 nM) < α-Cl-TMC (992
nM) < α-I-TMC (3.15 µM) < α-H-TMC (4.44 µM) < α-F-TMC (12.9
µM). The IC50 value for α-COOEt-TMC (6.65 µM) did not match
the expected correlation. In addition, α-p-NO2-C6H4-TMC was
considerably less active than one would have predicted from its
k2 value. However, these observations are in agreement with our
previous study and may be explained by electrophilicity-inde-
pendent intracellular interactions or reactions. The relatively
weak inhibition of NO production by α-CN-TMC and α-NO2-
TMC (Table 1) could result from their very strong electrophili-
city, possibly causing their inactivation.
α-X-TMCs inhibit TNF secretion by LPS-stimulated primary
human macrophages
Having observed consistent eﬀects in diﬀerent assays, we
selected four α-X-TMCs with anti-inflammatory activity (X =
CF3, Br, Cl, and H) and two inactive α-X-TMCs (X = CN, NO2)
for further study. We wanted to ascertain that anti-inflamma-
tory eﬀects can also be observed with primary human cells,
not just with cell lines. Thus we tested the influence of the
compounds on TNF secretion by LPS-stimulated primary
human macrophages (Fig. 5A).
TNF levels in the cellular supernatant were measured by
ELISA after 24 h. Using α-X-TMCs at a concentration of 5 µM,
the following percentages of inhibition were found: α-Br-TMC
76%, α-CF3-TMC 70%, α-Cl-TMC 30%, α-H-TMC 25%,
α-CN-TMC 17%, and α-NO2-TMC 0%. At a concentration of
1 µM only α-Br-TMC (35%) and α-Cl-TMC (14%) inhibited TNF
release. The α-CF3-TMC response was highly variable amongst
the four donors tested and therefore appeared less pro-
nounced. We confirmed that decreases in TNF production
were not caused by cell death (data not shown). This result
demonstrated once again that α-Br-TMC, α-CF3-TMC and, to
Table 1 Inhibition of NO production in LPS-stimulated
RAW264.7 macrophages by α-X-TMCs. The α-X-TMCs are listed in order
of relative thiol reactivity (k2 values, decreasing from top to bottom)
α-X-TMC
Toxicity
limita [µM]
Maximum inhibition
of NO production [%]
(conc [µM])b
IC50 (NO
production)
[µM]
CN 25 16.4 ± 8.7 (1) nd
NO2 10 26.9 ± 7.9 (10) nd
CF3 0.5 84.6 ± 8.9 (0.5) 0.120 ± 0.062
Br 1 67.4 ± 11.7 (1) 0.640 ± 0.179
Cl 1 47.2 ± 14.6 (1) 0.992 ± 0.482
p-NO2-C6H4 10 35.8 ± 2.2 (10) nd
I 5 72.2 ± 9.7 (5) 3.15 ± 0.70
COOEt 10 66.8 ± 8.4 (10) 6.65 ± 0.53
H 10 96.9 ± 11.9 (10) 4.44 ± 1.29
F 25 86.6 ± 18.9 (25) 12.9 ± 5.6
p-OMe-C6H4 10 ns nd
Me 10 −34.7 ± 15.2 (5) nd
Ph 25 27.9 ± 13.4 (25) nd
COOH 25 20.8 ± 3.7 (25) nd
a Toxicity of chalcones was measured with the MTT assay in the
absence of LPS (no diﬀerences were found in the presence of LPS).
Concentrations causing cell viabilities > 80% after 24 h incubation
were assigned as non-toxic. b Stimulation with α-X-TMCs for 24 h in
the presence of 10 ng mL−1 LPS. ns, non-significant (no significant NO
inhibition observed); nd, not determined.
Fig. 5 Inﬂuence of selected α-X-TMCs on LPS-induced cytokine
expression. (A) TNF production of LPS-stimulated (100 ng mL−1) human
primary macrophages after 24 h incubation without (control) or with
α-X-TMCs; independent experiments with cells from four individual
donors were performed. TNF was determined in cellular supernatants by
(B) ELISA. (C) RT-PCR analysis of IL-6 and IL-8 mRNA levels in human
HeLa cells relative to LMNA (human Lamin A/C). HeLa cells were pre-
incubated with α-X-TMCs or DMSO (control) for 45–60 min prior to a
60 min stimulation with 30 ng mL−1 recombinant human TNF: (B) IL-6,
(C) IL-8. Data represent four (A) or three (B), (C) independent experi-
ments. Levels of signiﬁcance: ***, p < 0.001; **, p < 0.01; *, p < 0.05.
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lesser extent, α-Cl-TMC interfere with proinflammatory path-
ways – in this case inhibiting TNF release.
α-X-TMCs inhibit expression of IL-6 and IL-8 in TNF-
stimulated HeLa cells
Expression of the cytokines interleukin-6 (IL-6) and inter-
leukin-8 (IL-8) is stimulated by NF-κB transcriptional activity
and therefore predicted to be influenced by treatment with
α-X-TMCs. We tested the two strongest (α-CN-TMC, α-NO2-
TMC), two moderately strong (α-CF3-TMC and α-Br-TMC) and
two poor to very poor electrophiles (α-F-TMC and α-Me-TMC).
As expected, using TNF-stimulated HeLa cells, we found a
strong reduction of IL-6 and IL-8 mRNA levels upon treatment
with either α-CF3-TMC or α-Br-TMC (Fig. 5B and C). At 10 µM
both compounds almost completely abolished the induction
of IL-6 and IL-8 (94–99% inhibition). Whilst α-Br-TMC still
showed a pronounced eﬀect at 0.5 µM, α-CF3-TMC gave similar
inhibition ratios at 2 µM, but not below. Both compounds
were about 10 fold more active than the established NF-κB
inhibitor curcumin14 which served as a positive control and
reference (Fig. 5B and C).
α-Br-TMC inhibits TNF-induced nuclear translocation of
NF-κB p65 in HeLa cells
Having observed that NF-κB-dependent transcription of IL-6
and IL-8 was inhibited by α-CF3-TMC and α-Br-TMC, we aimed
to confirm that this eﬀect was due to the inhibition of NF-κB
activation. We therefore monitored nuclear translocation of
NF-κB in TNF stimulated HeLa cells in the presence or absence
of 10 µM α-Br-TMC.
While cytosolic levels of NF-κB p65 were largely unaﬀected
by α-Br-TMC or TNF, TNF-induced nuclear translocation of NF-
κB p65 was significantly reduced after pre-treatment with
α-Br-TMC (Fig. 6). This result demonstrated that α-Br-TMC
inhibits the NF-κB activation pathway upstream of nuclear
translocation.
Experimental
Chemicals and reagents
α-X-TMCs were prepared as described previously.8 Compounds
were purchased from the following commercial sources and
used without further purification: curcumin (B6938), hemin
and gelatin (from cold water fish skin) from Sigma (Germany),
NADPH from AppliChem (Germany), OPD (ortho-phenylene-
diamine dihydrochloride) from Acros Organics (Belgium),
bilirubin from Frontier Scientific (UK), Triton X-100 from
Merck (Germany), xanthohumol (XN) from Carl Roth
(Germany) or, alternatively, XN was obtained as hop-derived
ethanolic extract with 80% purity (Hallertauer Hopfenverwer-
tungsgesellschaft, Mainburg, Germany) and purified by silica
gel column chromatography with n-hexane–ethyl acetate as
previously described (purity (HPLC) > 99%).15
Cell viability test (MTT assay) on RAW264.7 cells
Murine macrophage RAW264.7 cells were cultured in RPMI
1640 medium supplemented with 10% heat-inactivated fetal
calf serum (FCS) and 2 mM glutamine (Biochrom, Germany) at
37 °C in humidified air containing 5% CO2. In order to
exclude cytotoxicity of the compounds a MTT assay was per-
formed and the eﬀect of the compounds on cell viability com-
pared to control cells was determined. The results were
published in a previous study of the α-X-chalcones.8b
ELISA-based HO-1 activity assay on RAW264.7 cells
The assay was performed as previously reported via in situ for-
mation of bilirubin by HO-1/BVR activity and quantification of
bilirubin by ELISA.9
Briefly, RAW264.7 macrophages (8 × 104 cells per well) were
placed in 96-well plates for 24 h and then treated with com-
pounds for 3, 6 and 24 h. Controls received no compounds.
After cell lysis (40 mM TRIS-HCl, pH 7.4, 250 mM sucrose,
137 mM NaCl, 10% (v/v) glycerin, 2 mM EDTA, 0.1% (v/v)
Triton X-100, complete protease inhibitor cocktail, Roche Diag-
nostics, Germany) the HO-1 reaction mixture (40 mM
TRIS-HCl, pH 7.4, 250 mM sucrose, 0.3 mM NADPH, 1.0 ng
BVR (biliverdin reductase, Stressgen, Assay Designs, USA) and
2.5 µM hemin) was applied for 1 h. Bilirubin standards
(0.50–2500 × 10−9 M bilirubin) were prepared in 40 mM
TRIS-HCl, pH 7.4, 250 mM sucrose and combined with super-
natant of whole cell lysates from control cells. Bilirubin was
quantified by using an excess of the anti-bilirubin antibody
24G7 from mouse (Shino-Test, Japan, 0.57 µg µL−1 in 1%
G-PBS with 0.5 mM sodium salicylate) and subsequently ana-
lyzing the unbound 24G7 by ELISA. To trap 24G7 an immuno-
plate (Nunc, Denmark) coated with a bilirubin-BSA conjugate
(0.35 µg protein per well) was utilized. Detection was done
using a HRP-conjugated anti-mouse antibody from goat (Rock-
land, USA; 1 : 10 000) with a freshly prepared substrate solution
(0.40 g mL−1 OPD and 0.40 µL mL−1 30% H2O2 in citrate
buﬀer, pH 5.0). After quenching with aqueous 3 M H2SO4 the
absorbance was measured at 492 nm (Multiskan Spectrum,
Thermo, Finland). The sigmoidal calibration curve was fit to a
Fig. 6 Inhibition of TNF-induced nuclear translocation of NF-κB p65 by
α-Br-TMC. Western blot analysis of cytosolic (C) and nuclear (N) extracts
stained with an anti-NF-κB p65 antibody. HeLa cells were pre-incubated
with α-Br-TMC or DMSO (vehicle) for 45 min prior to a 15 min stimu-
lation with 30 ng mL−1 recombinant human TNF. One representative
blot out of three independent experiments is shown. Immunostaining of
α-tubulin served as a quality control for cellular fractionation.
Paper Organic & Biomolecular Chemistry
3044 | Org. Biomol. Chem., 2015, 13, 3040–3047 This journal is © The Royal Society of Chemistry 2015
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
4 
Ja
nu
ar
y 
20
15
. D
ow
nl
oa
de
d 
on
 1
6/
02
/2
01
6 
10
:2
3:
31
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
four parameter logistic equation to determine unknown bili-
rubin concentrations. HO activity was calculated as pmol bili-
rubin formed per hour and per milligram of protein (pmol BR
h−1 mg−1) and expressed as fold HO-1 activity compared to
control cells.
AREc32 (human mammary epithelial adenocarcinoma MCF7)
cells
AREc32 is a reporter cell line derived from the human
mammary epithelial adenocarcinoma MCF7 cells. It contains a
luciferase reporter gene construct under the control of eight
copies of the Nrf2 binding site ARE.11 AREc32 cells were cul-
tured at 37 °C and 5% CO2 in a humidified atmosphere in
complete DMEM medium supplemented with 10% heat-inacti-
vated FCS, 2 mM glutamine, 100 U mL−1 penicillin and 100 μg
mL−1 streptomycin (medium and all supplements from Gibco,
USA), and maintained under antibiotic selection (0.8 mg mL−1
G418 (Sigma, Germany)).
Cytotoxicity assay on α-X-TMC-stimulated AREc32 cells
Biomass content was assessed by sulforhodamine B (SRB,
Sigma, Germany) staining.12 Briefly, AREc32 cells were seeded
and treated as for the luciferase reporter assay. Detached cells
in the supernatant were discarded and attached cells were
fixed with 10% trichloroacetic acid for 30 min at 4 °C. Then,
the plate was rinsed with distilled water, dried and stained for
15 min with a 0.4% solution of SRB in 1% acetic acid, washed
several times with 1% acetic acid and dried again. The dye was
eluted with 10 mM TRIS base followed by the measurement of
OD at 490 nm and 515 nm (SpectraMax M5e Microplate
reader, Molecular Devices, USA).
Luciferase reporter assay on α-X-TMC-stimulated AREc32 cells
AREc32 cells were seeded at a density of 9 × 103 per well in 50
µL growth medium in 384-well plates. After 22 h compounds
were added to obtain final concentrations in the range
between 1.56–100 µM. Each concentration was tested in quad-
ruplicate. An equal volume of vehicle was added to the control
wells (0.016–1% DMSO). The reporter assay was performed as
described previously.11 For normalization all values were
divided by vehicle control values, yielding the fold change rela-
tive to the control. Further, the luciferase activity was normal-
ized to biomass content.
iNOS inhibition test (Griess assay) on RAW264.7 cells
The produced NO which is accumulated as nitrite in the
culture medium was quantified using the Griess reaction.
RAW264.7 macrophages (8 × 104 cells per well) were plated in
96-well plates and allowed to attach for 24 h. Stock solutions of
compounds were prepared in DMSO (100 mM) and stored at
−20 °C. Test concentrations were freshly prepared by diluting
the stock solution in culture medium in presence and absence
of 10 ng mL−1 LPS and then incubated with the cells for 24 h.
The final concentration of DMSO was ≤0.025% and the total
assay volume was 100 µL. 50 µL of culture medium was mixed
with 50 µL of Griess reagent (0.1% NED (N-1-naphtylethylene-
diamine dihydrochloride), 1% sulfanilamine, 0.35% phospho-
ric acid in water) and incubated for 15 min at room
temperature. The absorbance was measured at 560 nm (Multi-
skan Spectrum, Thermo, Finland) at 25 °C and nitrite concen-
trations were calculated from a standard curve established
with serial dilutions of NaNO2 (0/5/10/25/50 µM) in culture
medium. Nitrite production was expressed as percent com-
pared to control cells incubated with 10 ng mL−1 of LPS.
Quantification of TNF in LPS-stimulated human macrophages
treated with α-X-TMCs
Macrophages were diﬀerentiated from human monocytes,
obtained by leukapheresis of healthy donors, followed by
density gradient centrifugation over Ficoll/Hypaque and separ-
ation by countercurrent centrifugation (J6M-E centrifuge, Beck-
mann, Germany) as described previously.16 The purity (> 85%)
of the monocytes was determined by morphology and the
expression of CD14 antigen. For the diﬀerentiation of macro-
phages, monocytes were cultured on teflon foils for 7 days at a
concentration of 1 × 106 cells mL−1 in RPMI 1640, 10% human
AB-serum (both from PAN Biotech, Germany), 2 mM glutamine
and 50 U mL−1 penicillin–50 mg mL−1 streptomycin (all from
Gibco/Life Technologies, Germany) at 5% CO2 and 37 °C.
Thereafter, macrophages were harvested, counted and 0.2 ×
106 cells in 1 mL incubated overnight in 24-well plates with
100 ng mL−1 LPS (Enzo Life Sciences, Germany) for maturation
with or without the addition of α-X-TMCs with X = CN, NO2,
CF3, Br, Cl, H (0.5, 1, 5 µM). After 24 h, supernatants were har-
vested, frozen and later analyzed for cytokine production
according to the manufacturer’s instructions (DuoSet ELISA,
R&D Systems, Germany).
Inhibition of NF-κB activation assay in human HeLa cervical
cancer cells
HeLa cells (a kind gift from Daniela Männel, Institute of
Immunology, University of Regensburg) were grown in RPMI
1640 supplemented with 10% heat-inactivated FCS and 100 U
mL−1 penicillin and 100 μg mL−1 streptomycin (all PAN-Bio-
tech, Germany). The potential inhibitory eﬀect of synthetic
chalcones and curcumin on NF-κB activation was measured by
incubating HeLa cells for 45–60 min with the indicated con-
centration of compounds or DMSO as vehicle, prior to stimu-
lation with recombinant human TNF (30 ng mL−1; gift from
Daniela Männel) for 15 min (Western blot analysis) or 60 min
(gene expression analysis). DMSO was adjusted to 0.01%
(Western blot analysis) or 0.1% (gene expression analysis) in
all conditions. Following TNF stimulation, cells were washed
in cold PBS and harvested for either gene expression or
Western blot analysis. For gene expression analysis, cells were
lysed in the iScript RT-qPCR sample preparation reagent (Bio-
Rad Laboratories, Germany) and subjected to cDNA synthesis
using the iScript cDNA Synthesis kit (Bio-Rad Laboratories,
Germany), following the manufacturer’s instructions. Quanti-
tative PCR was performed on a RotorGene Q (Qiagen,
Germany) with SYBR Green I and HotStarTaq (Qiagen,
Germany). Data were normalized to human Lamin A/C (LMNA)
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mRNA as previously described,17 and expressed as relative
mRNA levels (% of vehicle or control). Forward and reverse
real-time PCR primers specific for human LMNA, IL-6 and
IL-8 have been described.18 Data shown represent the mean of
three independent experiments. For Western blot analysis,
cells were scrapped oﬀ mechanically; nuclear and cytosolic
protein fractionation and NF-κB p65 immunoblotting were per-
formed as previously described.18 Quality of the cytosolic and
nuclear extraction was verified by immunoblotting with an
antibody directed against the cytosolic marker α-tubulin
(Santa-Cruz Biotechnology, Germany; 1 : 200). Chemolumine-
scence detection was performed using Amersham ECL Prime
(GE Healthcare Life Sciences, Germany) and images were cap-
tured on an ImageQuant LAS 4000 mini imaging system (GE
Healthcare Life Sciences, Germany). The immunoblot shown
is representative of three independent experiments.
Data evaluation/statistical analysis
The data is presented as the mean ± SD of several independent
experiments (as indicated in figure captions) carried out in
duplicates, triplicates or quadruplicates depending on the assay.
A sigmoidal logistic function was used to fit dose–response
curves and determine IC50 values using a Microsoft Excel calcu-
lation sheet (Ed50plus, v1.0, April 2000, Mario H. Vargas,
Instituto Nacional de Enfermedades, Mexico). Comparison
between groups was made using a two-sided paired Student’s
t test. A p value < 0.05 was considered statistically significant.
Levels of significance: ***, p < 0.001; **, p < 0.01; *, p < 0.05.
Conclusion
The direct covalent modification of protein thiols by alkylating
agents can activate Nrf2 and inhibit NF-κB and hence lead to
the dampening of inflammatory responses.4 To exploit this
phenomenon for therapeutic interventions, fine tuning of elec-
trophilicity is desirable. If the electrophilicity is too low, the
compound is unlikely to be eﬀective at concentrations that are
pharmacologically accessible. If the electrophilicity is too high,
the compound may react non-specifically with a broad range
of protein thiols or may be neutralized by glutathione conju-
gation. In contrast, compounds with intermediate electrophili-
city may avoid rapid clearance and target a relatively narrow
range of proteins, namely those with exposed and/or activated
thiolate residues poised to be involved in protein redox regu-
lation, like those in Keap1 or NF-κB.
Thus, it appears critical to hit the right thiol reactivity
window.19 We pursued the strategy to first classify electro-
philes by in vitro kinetics (second order rate constant determi-
nation for the reaction with cysteamine), followed by probing
the same electrophiles for their cellular eﬀects. A similar
approach used theoretical chemistry calculations to predict the
electrophilicity of aryl nitriles, successfully explaining structure
activity relationships for the inhibition of cysteine proteases.20
Out of fourteen α-X-TMCs, three compounds stood out as
potent anti-inflammatory agents, namely α-CF3-TMC, α-Br-
TMC and α-Cl-TMC. These were highly eﬃcient in activating
Nrf2 and inhibiting NF-κB, with corresponding eﬀects on their
respective transcriptional gene products. Notably, suppression
of iNOS activity was observed with IC50 values in the nano-
molar range. Although alternative electrophilicity-independent
modes of action cannot be strictly ruled out at this point, the
inactivity of the most electrophilic compounds α-CN-TMC and
α-NO2-TMC can be rationalized by their predicted rapid reac-
tion with intracellular GSH, which is present at millimolar
concentrations.21
As a scaﬀold the chalcones facilitate straight forward access
to libraries of fine-tuned electrophiles, allowing detailed studies
of the relationship between electrophilicity and biological
activity. In future work such electrophiles may be linked to mole-
cules containing non-covalent recognition motifs, thus directing
the electrophilic warhead22 to particular protein targets.23
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